This study is being conducted to evaluate the efficacy and safety of lonapegsomatropin compared to somatropin. The research focuses on children and adolescents who experience growth failure or short stature, which means they are shorter than expected for their age. These conditions may be caused by several different disorders, such as Turner Syndrome, SHOX Deficiency, being small for gestational age, or idiopathic short stature, which is when short height occurs without a known medical cause.
Participants in the study will receive either lonapegsomatropin or somatropin through a subcutaneous injection, which is a method of delivering medication into the fatty layer just under the skin. The goal is to compare a weekly injection of the new medication to the daily use of the standard treatment. During the course of the study, height and growth progress will be monitored over a period of time to see how the different treatments affect development.



France
Germany
Italy
Romania
Spain